EKO / TSX Venture Exchange
MONTREAL, Jan. 8 /CNW Telbec/ - Noveko International Inc. ("Noveko" or
the "Company") announces that it has strengthened the management of its
subsidiary Noveko Inc., specializing in the development of its patented
antimicrobial filtration technology business. Its derivative products -
antimicrobial face masks, surgical respirators and antimicrobial air filters -
are currently at the marketing stage.
Formerly, the senior management of the subsidiary Noveko Inc. was fully
assumed by André Leroux, Chairman of the Board and Chief Executive Officer of
Noveko International Inc. The major developments over the past year and the
subsidiary's anticipated future growth required the creation of the position
of President and Chief Operating Officer of Noveko Inc. Gaston Lavallée,
Vice-President, Business Development of Noveko International Inc., has just
been appointed to this position.
Consequently, Noveko Inc. is now headed by André Leroux, who acts as the
subsidiary's Chairman of the Board and Chief Executive Officer, and
Gaston Lavallée, as President and Chief Operating Officer. In addition to his
new responsibilities within Noveko Inc., Mr. Lavallée will continue to act as
Vice-President, Business Development of Noveko International Inc.
"We are strengthening the management of Noveko Inc. in support of this
important subsidiary's growth strategy. Our goal is to increase our efficiency
and to take further advantage of the opportunities ahead of us in the global
market of antimicrobial face masks, surgical respirators and antimicrobial air
filters. Subsequent to the decisive milestones of the past year - which have
been well welcomed by the investment community - we are expanding our
distribution networks and intensifying the marketing of our products,"
indicated André Leroux.
Noveko International Inc. currently has four subsidiaries: S.A.S. ECM,
Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. ("BLI").
ECM specializes in the design and marketing of portable real-time ultrasound
scanners for use in veterinary and human medicine. Noveko Inc. develops the
Company's biomedical and environmental business, specifically its patented
antimicrobial filtration technology and derivative products (Noveko(TM)
antimicrobial face masks and air filters). SyMa specializes in the manufacture
of sanitizers, more specifically the antimicrobial products (for hands, feet
and surfaces) sold under the Azuro(TM) trademark. For its part, BLI
specializes in the custom processing and distribution of steel products based
on client specifications and designs. It has also developed and markets a line
of downdraft particle extraction tables for various markets. Operating since
September 2002, the Company was listed on the TSX Venture Exchange on
February 3, 2004.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer, (514) 344-3030; Alain Bolduc, President and Chief Operating
Officer, Noveko International Inc., (514) 344-3030, http://www.noveko.com